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ABSTRACT
The presence of tumor infiltrating lymphocytes is a favorable prognostic factor 
in cutaneous melanoma, but their clinicopathological significance in the intratumoral 
compartment compared to the peritumoral compartment is unclear. We investigated 
the clinicopathologic significance of tumor-infiltrating lymphocytes and lymphocyte 
score in intra- and peritumoral compartments in 177 Korean patients who had 
undergone surgical excision of cutaneous melanoma. No significant correlation was 
observed between various clinicopathologic factors and the presence of intratumoral 
lymphocytes. However, high peritumoral lymphocyte scores were associated with 
lower Clark levels (P = 0.001), shallower Breslow thicknesses (P = 0.006), and fewer 
mitotic counts (P = 0.01) than tumors with lower scores. There was a trend for longer 
disease-free survival in cases with peritumoral lymphocytes (P = 0.07) than those 
without peritumoral lymphocytes. In patients with acral lentiginous melanoma, a 
strong association between a high peritumoral lymphocyte score and shallow Clark 
level was apparent (P = 0.03), and the presence of peritumoral lymphocytes (P = 0.02) 
and a high intratumoral lymphocyte score (P = 0.04) was also associated with longer 
disease-free survival. Particularly, low intratumoral lymphocyte score remarkably 
affected tumor recurrence and distant metastasis in a multivariate analysis using Cox 
regression test (H.R. = 0.304, 95% C.I. = 0.078–1.185, P = 0.09). Thus, the presence 
of lymphocytes and high lymphocyte scores in the intratumoral and peritumoral 
compartments are valid prognostic factors in cutaneous melanoma.
INTRODUCTION
Malignant transformation of tissue destroys its 
normal structure and leads to an immune response that 
includes infiltration of the tissue with immune cells 
that target tumor cells [1]. Immune cell infiltration is 
an important protective mechanism and forms the basis 
for adoptive cell therapy in cancer treatment. The use of 
adoptive cell therapy in patients with cutaneous melanoma 
is particularly promising. The therapy entails initial 
lympho-depletion followed by administration of ex vivo 
expanded tumor infiltrating lymphocytes (TILs) and large 
doses of interleukin 2 (IL-2) and had an approximately 
50% response rate in patients with highly advanced and 
metastatic melanoma [2, 3]. Perhaps more important, it 
was effective in patients who had responded poorly to 
existing immumotherapies, such as treatment modalities 
based on IL-2 [4]. Adoptive cell therapy has been applied 
to cases of metastatic melanoma or lung cancer in which 
tumor cells evaded the immune cell attack in a process 
referred to as immunoediting [5]. Researchers sought to 
counteract immunoediting by reactivating the immune 
response after its inhibition by the tumor cells [3, 4, 6–8].
The application of immune cell infiltration in the 
treatment of cutaneous melanoma is increasing, despite 
some uncertainty as to its efficacy [9, 10]. Most studies 
have been of a small number of cases or did not include 
the identification of the type of infiltrating immune 
cells [11]. This has resulted in an uncertain prognosis for 
patients receiving the treatment. This uncertainty was 
addressed in a recent study of a large series of patients, 
in which it was observed that marked accumulation of 
TILs was a favorable prognostic factor [12]. Also, in a 
study sponsored by The Cancer Genome Atlas project, 
cutaneous melanoma patients with a higher lymphocyte 
score (LS) had longer overall survival than patients with 
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a lower LS, regardless of the histological subtype [13]. 
While these studies are promising, caution is still 
appropriate, as in these large-series studies, the location 
of the lymphocytes, whether in the intratumoral and 
peritumoral compartments, was not always determined. 
Therefore, the location of the infiltrating lymphocytes may 
be an important consideration.
It may also be important to consider the efficacy 
of TILs in melanomas of different histological subtypes. 
Generally, superficial spreading melanoma (SSM) is 
associated with favorable prognosis, while nodular 
melanoma (NM) has the poorest prognosis among 
cutaneous melanoma subtypes in the United States 
and East Asia [14, 15]. However, the effect of tissue 
on patient prognosis is uncertain and controversial for 
some cutaneous melanoma subtypes, including acral 
lentiginous melanoma (ALM). ALM usually occurs in 
areas that are rarely exposed to the sun, such as acral or 
mucosal sites and is associated with KIT mutations [16]. 
According to United States Surveillance, Epidemiology, 
and End Results (SEER) data [17], patients with ALM 
have poor prognoses compared to patients with other 
histologic subtypes of melanoma, whereas it follows an 
indolent course in a small number of patients studied in 
Korea [18].
In this study, we have evaluated the intratumoral 
and peritumoral compartments of cutaneous melanomas 
for the presence and number of TILs and assessed their 
correlation with various clinicopathological factors, 
including histological subtype. We related these 
parameters to prognostic significance. 
RESULTS
Basic clinicopathological features of cutaneous 
melanoma
The clinicopathological features of the 177 cutaneous 
melanoma cases studied were summarized in Table 1. 
Among these, there were 80 cases of ALM, 68 cases of 
NM, and 29 cases of SSM. Compared to the other subtypes 
of cutaneous melanoma, NM had a higher Clark level 
(P < 0.001), greater Breslow thickness (P < 0.001), more 
ulceration (P < 0.001), a higher mitotic count (P < 0.001), 
more lymphovascular invasion (P = 0.01), and more 
sentinel lymph node metastasis (P < 0.001).
Lymphocyte and lymphocyte score status in all 
cases studied
TILs were identified as associated with either 
the location of lymphocytes, whether intratumoral 
or peritumoral, and the LS for each population was 
calculated (Table 2). Sixty-six patients (37.29%) had 
intratumoral lymphocytes and 142 (82.23%) had 
peritumoral lymphocytes. High intratumoral lymphocyte 
score (I-LS) were observed for 27 patients (15.25%) and 
high peritumoral lymphocyte score (P-LS) were observed 
for 76 cases (42.94%). The representative microscopic 
photographs were presented in Figure 1.
Considering the intratumoral compartment, there 
were significant correlations between the presence of 
intratumoral lymphocytes and various clinical factors: 
the age of the patient at the time of surgery, the sex of 
the patient and incidence of ulceration (P < 0.05 for 
all). Meanwhile, there were no significant differences 
in pathologic factors according to the presence of 
intratumoral lymphocytes.
In contrast, there were significant correlations 
between the presence of peritumoral lymphocytes and 
various pathologic factors. Cases with high P-LS had 
lower Clark levels and shallower Breslow thickness than 
cases with low P-LS in histologic examination (P = 0.001 
and P = 0.006, respectively). This finding is consistent 
with the suggestion that high P-LS were present in the 
early stages of invasive cutaneous melanoma. In details, 
patients with high P-LS also had fewer mitotic counts 
(≤ 5 per 10 high-power fields) than patients with low 
P-LS (P = 0.01). There was an association between the 
presence of peritumoral lymphocytes and absence of 
lymphovascular invasion (P = 0.04) and less recurrence 
or metastasis (P = 0.09), although clinical follow-up data 
did not reveal a correlation between P-LS and tumor 
recurrence, distant metastasis or patients’ survival.
Lymphocyte status and lymphocyte score status 
in each histological subtype
Next, we analyzed clinicopathologic features 
according to lymphocytic infiltration in major histological 
subtypes of cutaneous melanoma. There were no 
significant differences with respect to location of the 
lymphocytes and the parameters measured in either NM 
or SSM (P > 0.05 for all; Supplementary Tables 1–4 in the 
Supplementary Data). 
However, in ALM, cases with high P-LS had lower 
Clark levels and tended to have shallower Breslow thickness 
(P = 0.03 and P = 0.07, respectively, Table 3). Among this 
subtype, cases with peritumoral lymphocytes had less 
recurrence and metastasis (P = 0.04), which is consistent 
with our findings when we considered all cases combined 
(Table 2). In the cases of ALM, we also noted more 
intratumoral lymphocytes in older patients and patients with 
ulceration (P = 0.07 and P = 0.005, respectively, Table 3) 
and cases with high I-LS were associated with less frequent 
recurrence or metastasis (P = 0.03). 
Clinicopathologic significance according to the 
combination of lymphocyte status or score in all 
cases studied and acral lentiginous melanoma
Among 177 cases, 60 presented with lymphocytes in 
both intra- and peritumoral compartments. To investigate 
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Table 1: Clinicopathological characteristics of 177 invasive cutaneous melanomas according to the 
histologic subtype
Variables Case No.
ALM NM SSM P valuen = 80 (%) n = 68 (%) n = 29 (%)
Age
 < 60 years 95 39 (48.8) 39 (57.4) 17 (58.6) 0.49
 ≥ 60 years 82 41 (51.3) 29 (42.6) 12 (41.4)
Gender
 Male 86 41 (51.3) 34 (50.0) 11 (37.9) 0.45
 Female 91 39 (48.8) 34 (50.0) 18 (62.1)
SLNMa
 Absent 98 55 (85.9) 29 (50.0) 14 (93.3) < 0.001
 Present 39 9 (14.1) 29 (50.0) 1 (6.7)
Recurrence / Metastasis
 Absent 131 64 (80.0) 41 (60.3) 26 (89.7) 0.003
 Present 46 16 (20.0) 27 (39.7) 3 (10.3)
Survival
 Alive 136 65 (81.3) 43 (63.2) 28 (96.6) 0.001
 Expired 41 15 (18.8) 25 (36.8) 1 (3.4)
Follow-up period, mob 40 (47.5) 21 (28.3) 36 (44.0) 0.001
Clark level
 II or III 47 27 (33.8) 4 (5.9) 16 (55.2) < 0.001
 IV or V 130 53 (66.3) 64 (94.1) 13 (48.8)
Breslow thickness
 ≤ 1.00 mm 48 25 (31.3) 3 (4.4) 20 (69.0) < 0.001
 1.01–2.00 mm 47 27 (33.8) 12 (17.6) 8 (27.6)
 2.01–4.00 mm 33 17 (21.3) 15 (22.1) 1 (3.4)
 > 4.00 mm 49 11 (13.8) 38 (55.9) 0 (0.0)
Ulceration
 Absent 126 58 (72.5) 39 (57.4) 29 (100) < 0.001
 Present 51 22 (27.5) 29 (42.6) 0 (0.0)
Mitosisc
 ≤ 5/10 HPFs 122 63 (78.8) 33 (48.5) 26 (89.7) < 0.001
 > 5/10 HPFs 55 17 (21.3) 35 (51.5) 3 (10.3)
LVI
 Absent 162 76 (95.0) 57 (83.8) 29 (100) 0.01
 Present 15 4 (5.0) 11 (16.2) 0 (0.0)
Mutation statusd
 BRAF mutant 12 2 (11.8) 10 (43.5) 0 (0.0) 0.06
 BRAF wild 30 15 (88.5) 13 (56.5) 2 (100)
ALM, acral lentiginous melanoma; NM, nodular melanoma; SSM, superficial spreading melanoma; SLNM, sentinel lymph 
node metastasis; LVI, lymphovascular invasion; mo, month. 
aSLNM was evaluated in 137 cases.
bFollow-up period was presented as median (interquartile range).
cMean mitotic count of 177 cases were 5.78/10HPFs.
dMutation study was performed in 42 cases. Two NRAS mutant cases belonged to BRAF wild group.
Oncotarget14762www.impactjournals.com/oncotarget
Table 2: Clinicopathological characteristics of 177 invasive cutaneous melanomas according to 
lymphocyte and lymphocyte score status of intratumoral and peritumoral compartment
Variables
Peritumoral lymphocyte Peritumoral lymphocyte score Intratumoral lymphocyte Intratumoral lymphocyte score
Present (%) Absent (%)
P-value
High (%) Low (%)
P-value
Present (%) Absent (%)
P-value
High (%) Low (%)
P-value
(n = 142) (n = 35) (n = 76) (n = 101) (n = 66) (n = 111) (n = 27) (n = 150)
Age
 < 60 years 77 (54.2) 18 (51.4) 0.77 40 (52.6) 55 (54.5) 0.81 28 (42.4) 67 (60.4) 0.02 10 (37.0) 85 (56.7) 0.06
 ≥ 60 years 65 (45.8) 17 (48.6) 36 (47.4) 46 (45.5) 38 (57.6) 44 (39.6) 17 (63.0) 65 (43.3)
Gender
 Male 66 (46.5) 20 (57.1) 0.26 41 (53.9) 45 (44.6) 0.22 36 (54.5) 50 (45.0) 0.22 18 (66.7) 68 (45.3) 0.04
 Female 76 (53.5) 15 (42.9) 35 (46.1) 56 (55.4) 30 (45.5) 61 (55.0) 9 (33.3) 82 (54.7)
Histologic subtype
 ALM 62 (43.7) 18 (51.4) 0.36 36 (47.4) 44 (43.6) 0.17 33 (50.0) 47 (42.3) 0.43 15 (55.6) 65 (43.3) 0.47
 NM 54 (38.0) 14 (40.0) 24 (31.6) 44 (43.6) 25 (37.9) 43 (38.7) 9 (33.3) 59 (39.3)
 SSM 26 (18.3) 3 (8.6) 16 (21.1) 13 (12.9) 8 (12.1) 21 (18.9) 3 (11.1) 26 (17.3)
Clark level
 II or III 42 (29.6) 5 (14.3) 0.07 30 (39.5) 17 (16.8) 0.001 16 (24.2) 31 (27.9) 0.59 9 (33.3) 38 (25.3) 0.39
 IV or V 100 (70.4) 30 (85.7) 46 (60.5) 84 (83.2) 50 (75.8) 80 (72.1) 18 (66.7) 112 (74.7)
Breslow thickness
 ≤ 1.00 mm 42 (29.6) 6 (17.1) 0.16 28 (36.8) 20 (19.8) 0.006 15 (22.7) 33 (29.7) 0.42 9 (33.3) 39 (26.0) 0.44
 1.01–2.00 mm 40 (28.2) 7 (20.0) 23 (30.3) 24 (23.8) 22 (33.3) 25 (22.5) 8 (29.6) 39 (26.0)
 2.01–4.00 mm 25 (17.6) 8 (22.9) 13 (17.1) 20 (19.8) 11 (16.7) 22 (19.8) 6 (22.2) 27 (18.0)
 > 4.00 mm 35 (24.6) 14 (40.0) 12 (15.8) 37 (36.6) 18 (27.3) 31 (27.9) 4 (14.8) 45 (30.0)
Ulceration
 Absent 103 (72.5) 23 (65.7) 0.43 58 (76.3) 68 (67.3) 0.19 41 (62.1) 85 (76.6) 0.04 20 (74.1) 106 (70.7) 0.72
 Present 39 (27.5) 12 (34.3) 18 (23.7) 33 (32.7) 25 (37.9) 26 (23.4) 7 (25.9) 44 (29.3)
Mitosisa
≤ 5/10 HPFs 98 (69.0) 24 (68.6) 0.96 60 (78.9) 62 (61.4) 0.01 48 (72.7) 74 (66.7) 0.40 22 (81.5) 100 (66.7) 0.13
> 5/10 HPFs 44 (31.0) 11 (31.4) 16 (21.1) 39 (38.6) 18 (27.3) 37 (33.3) 5 (18.5) 50 (33.3)
LVI
 Absent 133 (93.7) 29 (82.9) 0.04 70 (92.1) 92 (91.1) 0.81 59 (89.4) 103 (92.8) 0.43 25 (92.6) 137 (91.3) 0.99
 Present 9 (6.3) 6 (17.1) 6 (7.9) 9 (8.9) 7 (10.6) 8 (7.2) 2 (7.4) 13 (8.7)
SLNMb
 Absent 78 (71.6) 20 (71.4) 0.99 41 (75.9) 57 (68.7) 0.36 38 (67.9) 60 (74.1) 0.43 15 (65.2) 83 (72.8) 0.46
 Present 31 (28.4) 8 (28.6) 13 (24.1) 26 (31.3) 18 (32.1) 21 (25.9) 8 (34.8) 31 (27.2)
Mutation statusc
 BRAF mutant 11 (35.5) 1 (9.1) 0.13 6 (33.3) 6 (25.0) 0.55 7 (38.9) 5 (20.8) 0.20 3 (60.0) 9 (24.3) 0.13
 BRAF wild 20 (64.5) 10 (90.9) 12 (66.7) 18 (75.0) 11 (61.1) 19 (79.2) 2 (40.0) 28 (75.7)
Recurrence /Metastasis
 Absent 109 (76.8) 22 (62.9) 0.09 60 (78.9) 71 (70.3) 0.19 50 (75.8) 81 (73.0) 0.68 23 (85.2) 108 (72.0) 0.15
 Present 33 (23.2) 13 (37.1) 16 (21.1) 30 (29.7) 16 (24.2) 30 (27.0) 4 (14.8) 42 (28.0)
Survival
 Alive 110 (77.5) 26 (74.3) 0.69 60 (78.9) 76 (75.2) 0.56 52 (78.8) 84 (75.7) 0.64 21 (77.8) 115 (76.7) 0.90
 Expired 32 (22.5) 9 (25.7) 16 (21.1) 25 (24.8) 14 (21.2) 27 (24.3) 6 (22.2) 35 (23.3)
ALM: acral lentiginous melanoma; NM: nodular melanoma; SSM: superficial spreading melanoma; HPF: high-power filed; LVI: lymphovascular invasion; SLNM: sentinel lymph node metastasis.
aMean mitotic count of 177 cases were 5.78/10HPFs.
bSLNM was Evaluated in 137 cases.
cMutation study was performed in 42 cases. Two NRAS mutant cases belonged to BRAF wild group.
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the relationship between various clinicopathologic factors 
and lymphocytes in both compartments, the cases were 
divided into four groups (Supplementary Table 5 in the 
Supplementary Data): absence of lymphocytes in both 
compartments (29 cases, 16.4%), intratumoral lymphocytes 
only (6 cases, 3.4%), peritumoral lymphocytes only 
(82 cases, 46.3%), and lymphocytes in both compartments 
(60 cases, 33.9%). The absence of lymphocytes in both 
compartments was associated with a deeper Breslow 
thickness (P = 0.005). When ulceration was present, 
lymphocytic infiltration in both compartments was less 
likely compared with tumors without ulcerations (P = 0.02). 
With respect to LS, the cases were divided into four 
subgroups (Supplementary Table 6 in Supplementary Data): 
Low LS in both compartments (92 cases, 51.9%), high LS 
only in the intratumoral compartment (9 cases, 5.1%), high 
LS only in the peritumoral compartment (58 cases, 32.8%), 
and high LS in both compartments (18 cases, 10.2%). Cases 
with high LS in both compartments or the peritumoral 
compartment alone had a significantly shallower Clark level 
and Breslow thickness (P = 0.009 and 0.003, respectively). 
In addition, these two subgroups with high P-LS tended 
toward lower mitotic counts (≤ 5 per 10 high-power fields) 
compared with other subgroups (P = 0.06).
We separately analyzed clinicopathologic features 
of ALM according to tumor compartments. Cases with 
lymphocytes in any compartment had a significantly lower 
incidence of recurrence or metastasis than other cases 
(Supplementary Tables 7, 8 in the Supplementary Data, 
P = 0.04). However, there were no significant correlations 
between LS and various clinicopathologic factors 
(Supplementary Table 8 in the Supplementary Data).
Lymphocyte and mutation status
We also analyzed the correlation between 
lymphocyte infiltration and cutaneous melanoma mutation 
status. Among 177 cases, mutation study findings from 
the time of diagnosis were available for 42. The mutation 
studies performed were as follows: BRAF only (15 cases), 
BRAF/KIT (24 cases), and BRAF/NRAS (3 cases). 
Twelve and two cases had BRAF and NRAS mutations, 
respectively. The remaining 28 cases were negative for 
mutations. 
BRAF mutations were frequently observed in 
patients with NMs (P = 0.06, Table 1). In addition, BRAF 
mutations tended to be associated with the presence of 
peritumoral lymphocytes, although this was not significant 
(P = 0.13, Table 2). There was no significant correlation 
between LS and mutation status for any histologic 
subtype (Table 3 and Supplementary Tables 1–2 in the 
Supplementary Data).
Survival analysis
All 177 patients were clinically followed up, and there 
were 46 incidences of loco-regional recurrence or systemic 
metastasis and 41 deaths (Table 1). In Kaplan-Meier analysis 
based on the histological subtype, NM had the poorest 
prognosis (Figure 2). The prognosis for patients with SSM 
was favorable with respect to disease-free survival (DFS) 
and overall survival (OS) (P < 0.001 for both).
Considering the group together, patients with 
peritumoral lymphocytes and a high P-LS tended 
to have longer DFS than those without peritumoral 
lymphocytes or low P-LS, but the differences were not 
significant (P = 0.07, Figure 3A and P = 0.14, Figure 3B, 
respectively). The presence or absence of intratumoral and 
peritumoral lymphocytes and their respective LS did not 
affect overall survival (P > 0.05 for all, Supplementary 
Figure 1 in the Supplementary Data).
When histological subtypes were compared, there was 
no significant association between NM, SSM, and ALM 
with respect to the presence of lymphocytes or LS and DFS 
and OS (P > 0.05 for all; Supplementary Figures 2–4 in the 
Supplementary Data). However, patients with ALM whose 
tumors had peritumoral lymphocytes and high I-LS had 
significantly longer DFS (P = 0.02, Figure 3C and P = 0.04, 
Figure 3D, respectively). We conclude that both peritumoral 
lymphocytes and high I-LS extended DFS in these patients.
Figure 1: Microscopic examples of low and high lymphocyte scores in the intratumoral and peritumoral compartments 
of cutaneous melanomas. Representative microphotographs of the intratumoral and peritumoral lymphocyte scores with original 
magnification ×100 (H&E).
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For adjustment of parameters affecting a patient’s 
survival, multivariable analysis was performed using Cox 
regression test (Table 4). When we assessed a total of 177 
melanoma patients, male gender affected tumor recurrence 
and distant metastasis (H.R. = 2.354, 95% C.I. = 1.044–
5.304, P = 0.04) and OS (H.R. = 2.552, 95% C.I. = 1.071–
6.078, P = 0.03), respectively. Metastasis to a sentinel lymph 
node also affected tumor recurrence and distant metastasis 
(H.R. = 2.525, 95% C.I. = 1.050–6.071, P = 0.04). Although 
it was not statistically significant, low I-LS affected tumor 
recurrence and distant metastasis (H.R. = 0.304, 95% C.I. 
= 0.078–1.185, P = 0.09). When we analyzed patients’ 
Table 3: Clinicopathological characteristics of 80 acral lentiginous melanomas according to 
lymphocyte and lymphocyte score status of intratumoral and peritumoral compartment
Variables
Peritumoral lymphocyte Peritumoral lymphocyte score Intratumoral lymphocyte Intratumoral lymphocyte score
Present (%) Absent (%)
P-value
High (%) Low (%)
P-value
Present (%) Absent (%)
P-value
High (%) Low (%)
P-value
(n = 62) (n = 18) (n = 36) (n = 44) (n = 33) (n = 47) (n = 15) (n = 65)
Age
 < 60 years 30 (48.4) 9 (50.0) 0.90 15 (41.7) 24 (54.5) 0.25 12 (36.4) 27 (57.4) 0.07 5 (33.3) 34 (52.3) 0.19
 ≥ 60 years 32 (51.6) 9 (50.0) 21(58.3) 20(45.5) 21 (63.6) 20 (42.6) 10 (66.7) 31 (47.7)
Gender
 Male 29(46.8) 12(66.7) 0.14 22 (61.1) 19 (43.2) 0.11 18 (54.5) 23 (48.9) 0.62 10 (66.7) 31 (47.7) 0.19
 Female 33 (53.2) 6 (33.3) 14 (38.9) 25 (56.8) 15 (45.5) 24 (51.1) 5 (33.3) 34 (52.3)
Clark level
 II or III 23 (37.1) 4 (22.2) 0.24 17 (47.2) 10 (22.7) 0.03 10 (30.3) 17 (36.2) 0.59 8 (53.3) 19 (29.2) 0.08
 IV or V 39 (62.9) 14 (77.8) 19 (52.8) 34 (77.3) 23 (69.7) 30 (63.8) 7 (46.7) 46 (70.8)
Breslow thickness
 ≤ 1.00 mm 22 (35.5) 3 (16.7) 0.35 16 (44.4) 9 (20.5) 0.07 8 (24.2) 17 (36.2) 0.68 6 (40.0) 19 (29.2) 0.36
 1.01–2.00 mm 21 (33.9) 6 (33.3) 11 (30.6) 16 (36.4) 13 (39.4) 14 (29.8) 5 (33.3) 22 (33.8)
 2.01–4.00 mm 11 (17.7) 6 (33.3) 7 (19.4) 10 (22.7) 7 (21.2) 10 (21.3) 4 (26.7) 13 (20.0)
 > 4.00 mm 8 (12.9) 3 (16.7) 2 (5.6) 9 (20.5) 5 (15.2) 6 (12.8) 0 (0.0) 11 (16.9)
Ulceration
 Absent 46 (74.2) 12 (66.7) 0.56 25 (69.4) 33 (75.0) 0.58 18 (54.5) 40 (85.1) 0.005 9 (60.0) 49 (75.4) 0.34
 Present 16 (25.8) 6 (33.3) 11 (30.6) 11 (25.0) 15 (45.5) 7 (14.9) 6 (40.0) 16 (24.6)
Mitosisa
 ≤ 5/10 HPFs 48 (77.4) 15 (83.3) 0.75 29 (80.6) 34 (77.3) 0.72 26 (78.8) 37 (78.7) 0.99 13 (86.7) 50 (76.9) 0.41
 > 5/10 HPFs 14 (22.6) 3 (16.7) 7 (19.4) 10 (22.7) 7 (21.2) 10 (21.3) 2 (13.3) 15 (23.1)
LVI
 Absent 60 (96.8) 16 (88.9) 0.22 34 (94.4) 44 (95.5) > 0.99 32 (97.0) 44 (93.6) 0.64 15 (100) 61 (93.8) > 0.99
 Present 2 (3.2) 2 (11.1) 2 (5.6) 2 (4.5) 1 (3.0) 3 (6.4) 0 (0.0) 4 (6.2)
SLNMb
 Absent 42 (96.8) 13 (96.8) 0.67 24 (82.8) 31 (88.6) 0.72 24 (80.0) 31 (91.2) 0.29 10 (71.4) 45 (90.0) 0.10
 Present 8 (3.2) 1 (3.2) 5 (17.2) 4 (11.4) 6 (20.0) 3 (8.8) 4 (28.6) 5 (10.0)
Mutation statusc
 BRAF mutant 2 (18.2) 0 (0.0) 0.52 1 (14.3) 1 (10.0) > 0.99 2 (28.6) 0 (0.0) 0.15 0 (0.0) 2 (12.5) > 0.99
 BRAF wild 9 (81.8) 6 (100) 6 (85.7) 9 (90.0) 5 (71.4) 10 (100) 1 (100) 14 (87.5)
Recurrence / Metastasis
 Absent 53 (85.5) 11 (61.1) 0.04 30 (83.3) 34 (77.3) 0.50 29 (87.9) 35 (74.5) 0.14 15 (100) 49 (75.4) 0.03
 Present 9 (14.5) 7 (38.9) 6 (16.7) 10 (22.7) 4 (12.1) 12 (25.5) 0 (0.0) 16 (24.6)
Survival
 Alive 51 (82.3) 14 (77.8) 0.73 29 (80.6) 36 (81.8) 0.89 28 (84.8) 37 (78.7) 0.49 13 (86.7) 52 (80.0) 0.72
 Expired 11 (17.7) 4 (22.2) 7 (19.4) 8 (18.2) 5 (15.2) 10 (21.3) 2 (13.3) 13 (20.0)
HPF: high-power field; LVI: lymphovascular invasion; SLNM: sentinel lymph node metastasis.
aMean mitotic count of 177 cases were 5.78/10HPFs.
bSLNM was Evaluated in 62 cases.
cMutation study was performed in 17 cases. One NRAS mutant case belonged to BRAF wild group.
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Figure 3: Kaplan-Meier survival analysis in intratumoral and peritumoral compartments. (A) Disease-free survival of all 
cases of cutaneous melanomas in the study, in the presence or absence of peritumoral lymphocytes. (B) Disease-free survival of all cases 
of cutaneous melanoma in the study, compared to the peritumoral lymphocyte scores. (C) Disease-free survival of 80 acral lentiginous 
melanomas in the presence or absence of peritumoral lymphocytes. (D) Disease-free survival of 80 acral lentiginous melanomas compared 
to the intratumoral lymphocyte score.
Figure 2: Survival of patients with cutaneous melanoma of different histological subtypes. (A) Disease-free survival. (B) 
Overall survival. ALM: acral lentiginous melanoma; NM: nodular melanoma; SSM: superficial spreading melanoma.
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prognosis by melanoma subtypes, any statistical significance 
was identified in multivariable analysis (Supplementary 
Table 9 in the Supplementary Data). 
DISCUSSION
TILs, produced by the immune system in response 
to the invasion by the tumor, are frequently observed 
in tumors, including those associated with cutaneous 
melanoma [19–21]. Their presence appears to be a 
favorable prognostic factor, regardless of the type 
of lymphocyte [22, 23], and they have been applied 
successfully in adoptive cell therapy [2]. However, 
reports on the prognostic impact and usefulness of TILs 
as a treatment modality have limitations, such as a small 
number of cases as well as inadequate consideration of 
both the lymphocyte subsets and the location of the 
lymphocyte, whether intratumoral or peritumoral [11].
Here, we analyzed a large series of invasive 
cutaneous melanoma and assessed the relationship between 
prognosis and the presence and location of the lymphocytes 
associated with the tumors. A newly developed parameter, 
LS, was used to assess the distribution and density of 
lymphocytes in the two compartments [12]. We believe 
this is the first report evaluating the effect of lymphocytes 
in the intratumoral and peritumoral compartments in 
invasive cutaneous melanoma. 
We assessed the presence of lymphocytes and LS 
in each compartment in different histological subtypes of 
melanoma. We observed that the presence of peritumoral 
Table 4: Multivariate analysis of 177 invasive cutaneous melanomas of the impact of variable 
linicopathologic factors on recurrence/metastasis and survival
Category Variables
Recurrence/Metastasis Survival
HR (95% CI) P-value HR (95% CI) P-value
Age < 60 years 1 1
≥ 60 years 0.939 (0.435–2.027) 0.87 1.949 (0.863–4.403) 0.11
Gender Female 1 1
Male 2.354 (1.044–5.304) 0.04 2.552 (1.071–6.078) 0.03
Histologic subtype ALM 1 1
NM 2.209 (0.825–5.914) 0.12 1.374 (.438–4.303) 0.59
SSM 0.718 (0.150–3.429) 0.68 N/A N/A
Clark level II or III 1 1
IV or V 1.608 (0.414–6.247) 0.49 1.508 (0.242–9.389) 0.66
Breslow thickness ≤ 1.00 mm 1 1
1.01–2.00 mm 1.193 (0.295–4.823) 0.80 0.949 (0.067–13.375) 0.97
2.01–4.00 mm 0.471 (0.089–2.476) 0.37 4.505 (0.400–50.677) 0.22
> 4.00 mm 0.640 (0.124–3.318) 0.60 6.344 (0.476–84.546) 0.16
Ulceration Absent 1 1
Present 1.187 (0.539–2.614) 0.67 1.597 (0.684–3.730) 0.28
Mitosis ≤ 5/10 HPFs 1 1
> 5/10 HPFs 1.130 (0.464–2.749) 0.79 0.582 (0.240–1.411) 0.23
LVI Absent 1 1
Present 1.026 (0.355–2.969) 0.96 0.947 (0.303–2.958) 0.93
SLNM Absent 1 1
Present 2.525 (1.050–6.070) 0.04 2.196 (0.844–5.715) 0.11
Intratumoral lymphocyte Absent 1 1
Present 1.638 (0.657–4.079) 0.29 0.772 (0.225–2.651) 0.68
Peritumoral lymphocyte Absent 1 1
Present 0.548 (0.214–1.400) 0.21 0.817 (0.267–2.500) 0.72
I-LS Low 1 1
High 0.304 (0.078–1.185) 0.09 1.855 (0.542–6.341) 0.33
P-LS Low 1 1
High 0.927 (0.387–2.219) 0.87 0.809 (0.255–2.568) 0.72
HR: hazard ratio; CI: confidence interval; ALM: acral lentiginous melanoma; NM: nodular melanoma; SSM: superficial 
spreading melanoma; HPF: high-power filed; LVI: lymphovascular invasion; SLNM: sentinel lymph node metastasis; I-LS: 
intratumoral lymphocyte score; P-LS: peritumoral lymphocyte score; N/A: Not applicable.
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lymphocytes was a favorable prognostic factor when 
all cases were considered together. When the cases of 
ALM were considered separately, a high LS in either 
compartment tended to be favorable. However, in NM and 
SSM, the presence of lymphocytes in both compartments 
and their associated LS were not correlated with any 
clinicopathological factor and did not affect DFS or OS. 
Finally, we interpret our findings to indicate that high LS 
is a favorable prognostic factor in ALM but not in other 
subtypes, although a previous study identified immune 
signatures associated with improved survival independent 
of subtypes of cutaneous melanoma [13].
According to both the literature and our results, 
SSM has a favorable prognosis while NM and ALM 
have poor prognoses [15]. The differences in prognoses 
may be due to the type of dominant growth phase of the 
histological subtypes [24]. However, it is unknown how 
the location of the lymphocytes might affect the prognosis 
of patients with histologically different tumors.
When considering the importance of the lymphocyte 
location, it is possible that the presence of intratumoral 
or peritumoral lymphocyte and LS may be affected by 
histological or genetic subtype. For instance, the NRAS 
mutation has been more frequently detected in NM than 
in other subtypes [25, 26]. Activation of the oncogenic 
RAS pathway by the NRAS mutation suppresses the 
immune response by decreasing expression of major 
histocompatibility complex on tumor-cell surfaces and 
recruitment of regulatory T lymphocytes [27]. In a large-
series study performed in the United States and Australia, 
when the NRAS mutation was present in melanoma, the 
tumor infiltrating lymphocyte grade was lower [28].
To our knowledge, this study is the first report on 
the prognostic impact of high LS in ALM. Although the 
mechanism is uncertain, we can assume that there was a 
lower incidence of the BRAF or NRAS mutations in these 
cases, which have poor prognoses [28, 29]. In addition, 
in our study, cases of ALM had more intratumoral 
lymphocytes and higher I-LS than other subtypes. Based 
on this finding, we suggest that high I-LS may increase 
DFS more in ALM than in the other subtypes.
The exact mechanism by which TILs can affect 
ALM prognosis has not been elucidated, but several 
hypotheses could explain our findings. Unlike ALM, 
other cutaneous melanoma subtypes frequently present 
ultraviolet signatures and harbor mutations in BRAF, 
RAS, and NF. Mutations in these genes can facilitate 
escape from immune responses via several mechanisms: 
suppression of antigen expression, recruitment of 
regulatory T lymphocytes, and impaired dendritic cell 
maturation [27, 30]. In addition to immunoediting, NRAS 
mutations decrease Fas receptor expression and the 
susceptibility to Fas-mediated apoptosis in melanoma [31]. 
ALM lacks ultraviolet signatures, so it is plausible that 
ALM may possess a unique tumor microenvironment 
compared to other cutaneous melanoma subtypes. This 
could explain the differential effects of TILs on tumor 
progression among the subtypes, but further studies are 
necessary to validate this hypothesis.
This study has several limitations. First, it was 
performed in a single institute and the lymphocyte scoring 
method and analysis of the clinicopathological factors 
should be independently validated. However, we expect 
that the calculation of LS of intratumoral and peritumoral 
lymphocytes will be highly reproducible and that the data 
from different observers will agree closely. A second 
concern is that the mutation study was not fully performed 
in this study. We did not find a significant correlation 
between the presence of intra- or peritumoral lymphocytes 
and LS and genomic subtypes of cutaneous melanoma. 
However, BRAF mutations tended to be associated with 
the presence of peritumoral lymphocytes. According to 
previous studies [28, 32], cutaneous melanomas with 
mutations in RAS had less lymphocytic infiltration than 
those with the BRAF mutation. This intriguing issue may 
be resolved with additional studies on the effect of these 
mutations on intratumoral or peritumoral lymphocytes.
Finally, we conclude that the presence of peritumoral 
lymphocytes in cutaneous melanoma is a favorable 
prognostic factor that affects Breslow thickness and DFS. 
In patients with ALM, a high I-LS increases DFS more 
than just the presence of the lymphocytes. We suggest 
that the presence or absence of lymphocytes and the LS 
in both the intratumoral and peritumoral compartment 
should be included in the pathology report of cutaneous 
melanoma. Further studies should elucidate the correlation 
between intratumoral or peritumoral lymphocyte status 
and molecular subtypes of cutaneous melanoma.
MATERIALS AND METHODS
Study population
A total number of 732 consecutively diagnosed 
Korean patients who had undergone surgical treatment for 
melanoma from January 2006 to August 2015 in Severance 
Hospital, Seoul, Republic of Korea, were included. Patients 
who had a previous history of cutaneous melanoma, uveal 
melanoma, mucosal melanoma, melanoma in situ, tumors 
that were unsuitable for microscopic evaluation, or who 
had undergone neoadjuvant treatment were excluded. 
One-hundred and seventy-seven cases remained and were 
selected for the study.
Various clinical factors―age at time of surgery, sex, 
length of follow-up after surgery, recurrence, metastasis, 
and survival―were obtained from medical records. DFS 
time was estimated from the date of the surgical resection to 
the date of the first loco-regional or systemic metastasis, or 
death without any type of relapse. OS time was calculated 
from the date of the first surgical resection to the date of 
the last follow-up, or time of death regardless of cause. 
Whole-section slides of tissues stained with hematoxylin 
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and eosin (H&E) were reviewed by two pathologists (C.K. 
Park and S.K. Kim). The pathological parameters including 
histological subtype, Clark level, Breslow thickness, 
ulceration, lymphovascular invasion, the presence or 
absence of sentinel lymph node metastasis, and the mutation 
analysis results performed at the time of diagnosis were 
obtained. Mitosis was counted in 10 high-power fields. 
This study was reviewed and approved by the Institutional 
Review Board at Severance Hospital (4-2015-0473).
Evaluation and scoring of intratumoral and 
peritumoral lymphocytes
According to the previous studies [1, 19], 
intratumoral lymphocytes were defined as lymphocytes 
located in the stroma of the tumor mass or inside the 
tumor cell nests. Peritumoral lymphocytes were defined 
as lymphocytes surrounding the tumor mass. Applying 
this definition, lymphocytes were assessed as intratumoral 
and peritumoral and evaluated by two independent 
pathologists. The LS for each case was calculated as 
previously described [13], but, briefly, was defined as the 
sum of the lymphocyte distribution and density scores. 
Scores ranged from 0 to 6. The lymphocyte distribution 
score, which ranged from 0 to 3, was defined as follows: 
0 = absence of lymphocytes within the tissue, 1 = presence 
of lymphocytes occupying < 25% of the tissue, 
2 = presence of lymphocytes occupying 25 to 50% of the 
tissue, and 3 = presence of lymphocytes occupying > 50% 
of tissue. Lymphocyte density, which ranged from 0 to 3, 
was defined as follows: 0 = absent, 1 = mild, 2 = moderate, 
and 3 = severe. Based on this scoring method, the LS 
of the intratumoral compartment and the peritumoral 
compartment were calculated. We considered LS from 0 
to 2 to be low and scores from 3 to 6 to be high. 
Mutation study
Genomic DNA was extracted from 10 μm sections 
cut from formalin-fixed paraffin-embedded (FFPE) tissue 
blocks using the Maxwell® CSC DNA FFPE extraction 
kit (Promega, Wisconsin, USA) and the Maxwell® CSC 
instrument. The genomic DNA was subjected to PCR 
amplification optimized for pyrosequencing analysis. 
The following program was used for PCR amplification: 
95°C for 15 minutes; followed by 45 cycles of 94°C for 30 
seconds, 59°C for 30 seconds, and 72°C for 30 seconds; 
and a final extension step of 72°C for 10 minutes. The 
sequences of the various PCR primers for BRAF, KIT, and 
NRAS genes are available on request.
After PCR analysis, single-stranded DNA suitable 
for pyrosequencing was prepared using the PyroMark Q24 
MDx Vacuum Workstation (QIAGEN, Hilden, Germany). 
Pyrosequencing was performed in a PyroMark Q24 MDx 
Instrument according to the manufacturer’s instructions. 
Sequencing data were analyzed using PyroMark Q24 
MDx Software 2.0.
Statistical analysis
Statistical calculations were performed with SPSS 
version 21.0 (SPSS Inc., Chicago, Illinois, USA). Chi-
square tests were performed to evaluate the relationship 
between lymphocytes in the two compartments and 
clinicopathological parameters. DFS and OS were 
estimated with the Kaplan-Meier method with the log-
rank test. Multivariate regression was analyzed using Cox 
proportional hazards model. Significance statements refer 
to P values of < 0.05 in two-tailed tests.
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